Doctor Web
Russian antivirus vendor behind the Dr.Web product line, privately held since 1992, with a customer base concentrated in Russia and former Soviet states.
Visit Website ↗ + Add to CompareOverview
Doctor Web is a Moscow, Russia-based antivirus and anti-malware vendor that develops the Dr.Web product line, endpoint antivirus, mail and gateway security, and mobile protection, for both consumer and enterprise customers, with its commercial base concentrated in Russia and other former-Soviet states including Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Moldova.
Tracing its technology back to 1992, when founder Igor Danilov built one of the earliest antivirus engines capable of detecting polymorphic viruses, Doctor Web remains a privately-held, self-funded company with no disclosed venture or institutional funding, reporting roughly $118 million in revenue and 250-350 employees as of recent estimates. Its products hold Russian FSB and Ministry of Defense certification for use in systems handling state-secret information, and the company was named alongside Kaspersky in a 2017 Ukrainian government sanctions action tied to the conflict over Crimea.
Doctor Web has also disclosed being the target of a serious cyberattack itself, taking its own servers offline in 2019 after detecting unauthorized access, a notable transparency move for a security vendor. Given its Russian government certifications and the current geopolitical climate around Russian-origin security software, a climate that has already led the US government to restrict a peer vendor, Kaspersky, from the US market, Western enterprise adoption of Dr.Web outside its existing regional base carries adoption and supply-chain-trust considerations beyond pure technical merit.
Innovation Matrix Assessment
Continues to update its Dr.Web engine and mobile and gateway products, but as a long-established, self-funded private company without disclosed institutional investment, its pace of innovation is not benchmarked publicly against global antivirus and EDR leaders.
Reports roughly $118M in revenue and 250-350 employees with offices in Moscow and St. Petersburg, real operational scale within its core Russian and CIS market, though small relative to global antivirus and endpoint-protection leaders.
No disclosed funding events, and its addressable market is effectively constrained to Russia and CIS states given broader geopolitical dynamics around Russian security software, limiting growth momentum outside that region.
Signature and heuristic antivirus is a mature, well-established technology category; Doctor Web is a long-standing incumbent within it rather than a source of new technical approaches.
A three-decade operating history and a large regional customer base support baseline technical viability, and independent testing labs have historically included Dr.Web in comparative AV testing; however, this research did not surface recent post-2023 independent Western testing-lab results, and the company's own claims about detection performance are otherwise vendor-stated.
Relevance for CISOs outside Russia and CIS is materially limited by geopolitical and supply-chain-trust concerns around Russian-origin security software with government certifications for handling state-secret systems, similar to concerns that led the US to restrict a comparable peer vendor, Kaspersky, from the US market.
Why CISOs Should Care
Relevant chiefly to organizations already operating within Russia or CIS states where Dr.Web has an established regional presence and local support; not a realistic option for most Western enterprises given current geopolitical and supply-chain-trust dynamics around Russian security software.
What Makes It Different
One of the longest-running independent, non-state-owned Russian antivirus vendors, notable for disclosing its own 2019 breach rather than concealing it, but otherwise a conventional signature and heuristic antivirus vendor.
The Matrix Verdict
37/100 — EMERGING / UNRANKED
A legitimate, long-tenured antivirus vendor within its home region, but its Russian government certifications and the current geopolitical climate around Russian security software meaningfully cap its relevance and adoptability for most CISOs outside Russia and CIS.
Editorial Note: Claims vs. Verified Findings
Revenue (roughly $118M) and employee-count figures are third-party estimates (Owler/Tracxn), not audited company disclosure. FSB and Ministry of Defense certification of Dr.Web products for state-secret-handling systems and the 2017 Ukrainian sanctions action are independently reported via the company's own certification announcements and press coverage; the 2019 breach disclosure is independently reported by BleepingComputer and SecurityWeek. No US OFAC SDN or BIS Entity List listing for Doctor Web was found as of this research.
Sources
Alternatives to Doctor Web
Unknown Cyber Inc.
Malware genomics platform using automated deep static analysis and code-lineage comparison to identify unseen malware, variants, and supply-chain…
Synack Inc
A penetration-testing-as-a-service platform pairing a vetted researcher community with AI-driven attack surface discovery for continuous security validation.
Horizon3.ai
Autonomous penetration testing company whose NodeZero platform self-attacks networks without persistent agents, aiming to replace annual manual pentests…
Airlock Digital
Application allowlisting (deny-by-default) platform that blocks unapproved executables, scripts, and processes to prevent ransomware and malware execution.
Cogent Security
Agentic AI platform that autonomously triages, investigates, and remediates vulnerabilities as a force multiplier for security teams.
Reality Defender
Deepfake and synthetic media detection company offering real-time detection across voice, video, image, and text for enterprises and…